分组1 - The Bureau of Labor Statistics is set to release January's nonfarm payrolls report, with expectations of minimal growth, forecasting an increase of 55,000 jobs compared to December's gain of 50,000 [2][6] - Ford Motor Company reported a significant earnings miss for its fourth quarter, with adjusted earnings per share at 13 cents, which is 32% below Wall Street's expectation of 19 cents, primarily due to $900 million in unexpected tariff costs and a fire at an aluminum plant [3][4] - Moderna's shares dropped over 10% after the FDA refused to review its application for an experimental flu shot, citing issues with the study design despite prior approval [7][8] 分组2 - Estée Lauder is suing Walmart for selling counterfeit beauty products on its online marketplace, claiming that the retailer facilitated the sales of fake items from third-party sellers [12][13] - The lawsuit follows a CNBC investigation into counterfeit beauty products on Walmart's site, with Estée Lauder alleging harmful conduct by Walmart [13][14] - Kalshi reported a significant trading volume during the Super Bowl weekend, with bets on Bad Bunny's first song exceeding $100 million, reflecting a year-over-year increase of 2,700% [16][18]

Core Viewpoint - Bausch Health Companies Inc. announces the opening of the 2026 Salix Gastrointestinal Health Scholars Program, providing scholarships to support students living with gastrointestinal diseases as they pursue higher education [1] Group 1: Scholarship Program Details - The program will award scholarships of up to $10,000 to 10 exceptional students living with GI diseases [1] - Applications are open to students attending or planning to attend a two- or four-year college, university, or advanced vocational/technical school for the 2026-2027 academic year [1] - The application period will close on May 6, 2026, with recipients notified in the summer of 2026 [1] Group 2: Eligibility and Categories - Scholarships are available in three categories: - Working and/or Single Parents Scholar Award for students who are working parents and/or single parents [1] - Graduate Scholar Awards for students pursuing graduate degrees [1] - Undergraduate Scholar Awards for students pursuing undergraduate degrees [1] Group 3: Company Overview - Bausch Health is a global, diversified pharmaceutical company focused on improving healthcare outcomes [1] - The company develops, manufactures, and markets products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals, and eye health [1] - Salix Pharmaceuticals, a part of Bausch Health, is one of the largest specialty pharmaceutical businesses in the world, focusing on innovative treatments for gastrointestinal diseases [1]

Core Insights - Citius Oncology has entered into an exclusive distribution agreement with Uniphar to expand access to LYMPHIR in Europe, marking its third international distribution partnership [1][2] - The agreement allows Uniphar to manage access and distribution of LYMPHIR in specific territories in Western and Eastern Europe through country-specific managed access programs [1] - LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) and is not yet approved for commercial use outside the United States [1][2] Company Overview - Citius Oncology, a subsidiary of Citius Pharmaceuticals, focuses on developing and commercializing novel targeted oncology therapies [2] - The initial market for LYMPHIR is estimated to exceed $400 million and is considered underserved by existing therapies [2] - Citius Oncology has robust intellectual property protections, including orphan drug designation and pending patents for immuno-oncology use [2] Product Information - LYMPHIR (denileukin diftitox-cxdl) is indicated for use in Stage I-III CTCL after at least one prior systemic therapy [1] - The drug works by binding to IL-2 receptors on cancer cells, leading to cell death through inhibition of protein synthesis [1] - In 2021, denileukin diftitox received regulatory approval in Japan for treating relapsed or refractory CTCL and peripheral T-cell lymphoma [1] Distribution Partner - Uniphar is an international healthcare services company that supports over 200 pharmaceutical and medical technology manufacturers [2] - The partnership with Citius Oncology aims to improve patient outcomes for those with relapsed or refractory CTCL [1][2] - Uniphar operates across 180 countries and integrates various services to support the full product lifecycle from research to commercialization [2]

DUBLIN and BRIDGEWATER, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report fourth quarter and full year 2025 financial results and conduct a conference call on Wednesday, February 25, 2026. The Company will issue a press release detailing its fourth quarter and full year 2025 financial results in the pre-market hours, followed by a conference call with senior management at 8:0 ...

Core Insights - OneSource Specialty Pharma has received approval for its generic version of Ozempic in Saudi Arabia, allowing it to enter a significant market for type-2 diabetes and weight-loss drugs [1][2] - The partnership with Hikma Pharmaceuticals PLC aims to meet the rising demand for affordable generic drug alternatives in the Middle East and North Africa (MENA) region [3][4] Company Strategy - OneSource will manufacture semaglutide at its Bengaluru facility, while Hikma will leverage its commercial reach to enhance the drug's availability [3] - The collaboration with Hikma, the largest pharmaceutical company in the MENA region by sales, is expected to provide a strong platform for scaling access to this therapy [4] Market Dynamics - OneSource is preparing for a significant increase in demand for generic semaglutide as Novo Nordisk is set to lose patent exclusivity in over 80 countries this year [5] - The company is fast-tracking a $100 million capacity expansion to capitalize on the global boom in weight-loss drugs [5] Financial Performance - In Q3, OneSource's revenue fell 26% year-over-year to ₹290.3 crore ($33.1 million) due to delays in semaglutide approvals in Canada [6] - The company's EBITDA dropped 88%, with the EBITDA margin contracting to 6% from 36% a year earlier [6] - OneSource aims to achieve $500 million in revenue by FY28 [6]

Core Viewpoint - Merck has received FDA approval for KEYTRUDA® and KEYTRUDA QLEX™ for treating adults with PD-L1+ platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer [1] Group 1: Product Approval - The FDA approved KEYTRUDA® (pembrolizumab) for the treatment of adults with PD-L1+ (Combined Positive Score [CPS] 1) [1] - KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) plus paclitaxel, with or without bevacizumab, is also approved for the same indication [1]

近日，河南省政府办公厅印发《河南省提升中药质量促进中医药产业高质量发展若干政策措施》，以23 条精准举措，为河南省中医药产业高质量发展绘制出清晰蓝图。即日起，河南日报开设"从一株草到一 条链"专栏，记者深入医院、科研院所、田间地头、智能车间，剖析一个院内制剂如何通过现代研发转 化为创新中药，关注一株药材如何凭借科技赋能实现优育优种，探访一家药企如何借力智能制造完成转 型升级……通过系列报道，感受河南省中医药产业高质量发展的脉动。 （来源：河南商报） 【河南中医一附院院内制剂出圈记丨#从一株草到一条链#】#院内制剂是如何炼成的# ...

Core Viewpoint - Jincheng Pharmaceutical announced that its subsidiary, Guangdong Jincheng Jinsuo Pharmaceutical Co., Ltd., and its wholly-owned subsidiary, Shanghai Jincheng Suzhi Pharmaceutical Co., Ltd., participated in the bidding for the continuation procurement organized by the National Organization for the procurement of drugs whose agreements have expired [1] Group 1 - The company is involved in the bidding process for seven drug varieties, including Cefotaxime Sodium Injection and Ceftazidime Injection, as part of the national procurement program [1]

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company's website at https://ir.beonemedicin ...

南财智讯2月11日电，白云山公告，其控股子公司广州白云山天心制药股份有限公司收到国家药监局核 准签发的《药品补充申请批准通知书》，注射用青霉素钠通过仿制药质量和疗效一致性评价。 ...